68Ga-NOTA-3PTATE-RGD

N/A

Report date: 2025/11/20 16:01:05

NME

Base Information

Drug Name68Ga-NOTA-3PTATE-RGD

Drug Alias Name68Ga-TATE-RGD68Ga-NOTA-3P-TATE-RGD68Ga-NOTA-3PTATE-RGD

ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68Ga +[5]

Mechanisms of ActionSomatostatin receptor 2 antagonistsIntegrin alpha-V/beta-3 antagonists

TargetsSomatostatin receptor 2Integrin alpha-V/beta-3

Therapy Area/IndicationsLung NeoplasmsMeningiomaCarcinoma, Neuroendocrine +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesPeking Union Medical College Hospital

China Registration ClassN/A

Develop Information

Active CompaniesPeking Union Medical College Hospital

Inactive CompaniesN/A

Active IndicationsLung NeoplasmsMeningiomaNeuroendocrine Tumors

Inactive IndicationsCarcinoma, Neuroendocrine

Other Information

ATC CodeN/A